Inception Therapeutics

Overview

Inception Therapeutics is a biotechnology company dedicated to developing disease-modifying therapies for neurodegenerative diseases. The company's primary focus is on [NLRP3 inflammasome](/entities/nlrp3-inflammasome) inhibitors designed specifically for central nervous system applications, with an initial emphasis on [Parkinson's disease](/diseases/parkinsons-disease).

Company Profile

| Attribute | Value |
|-----------|-------|
| Founded | 2020 |
| Headquarters | San Diego, California, USA |
| CEO | Dr. Robert H. Brown |
| Funding | Series A ($32M, 2021) |
| Focus | CNS NLRP3 inhibitors |
| Stage | Preclinical |

Scientific Foundation

Inception Therapeutics was founded by leading neuroscientists from UC San Diego and The Scripps Research Institute:

• Scientific founders: Dr. Stuart Lipton (neuroscience), Dr. John Reed (drug discovery)
• Focus: Translating basic NLRP3 research into CNS therapeutics
• Approach: Brain-specific optimization of NLRP3 inhibitors

The company's name reflects its "inception" concept—starting from the fundamental biology of neuroinflammation to create transformative therapies.

Science and Technology

CNS-Optimized NLRP3 Platform

Inception's platform is specifically designed for brain applications:

BBB penetration: High brain-to-plasma ratios (>0.5)

Microglial targeting: Enhanced activity in activated microglia

Sustained exposure: Once-daily oral dosing potential

Clean safety profile: No peripheral immune suppression

Mechanism in Parkinson's Disease

...

Overview

Inception Therapeutics is a biotechnology company dedicated to developing disease-modifying therapies for neurodegenerative diseases. The company's primary focus is on [NLRP3 inflammasome](/entities/nlrp3-inflammasome) inhibitors designed specifically for central nervous system applications, with an initial emphasis on [Parkinson's disease](/diseases/parkinsons-disease).

Company Profile

| Attribute | Value |
|-----------|-------|
| Founded | 2020 |
| Headquarters | San Diego, California, USA |
| CEO | Dr. Robert H. Brown |
| Funding | Series A ($32M, 2021) |
| Focus | CNS NLRP3 inhibitors |
| Stage | Preclinical |

Scientific Foundation

Inception Therapeutics was founded by leading neuroscientists from UC San Diego and The Scripps Research Institute:

• Scientific founders: Dr. Stuart Lipton (neuroscience), Dr. John Reed (drug discovery)
• Focus: Translating basic NLRP3 research into CNS therapeutics
• Approach: Brain-specific optimization of NLRP3 inhibitors

The company's name reflects its "inception" concept—starting from the fundamental biology of neuroinflammation to create transformative therapies.

Science and Technology

CNS-Optimized NLRP3 Platform

Inception's platform is specifically designed for brain applications:

BBB penetration: High brain-to-plasma ratios (>0.5)

Microglial targeting: Enhanced activity in activated microglia

Sustained exposure: Once-daily oral dosing potential

Clean safety profile: No peripheral immune suppression

Mechanism in Parkinson's Disease

Inception's approach targets the specific neuroinflammatory pathways active in PD:

• Trigger: Alpha-synuclein aggregates, mitochondrial dysfunction
• Cellular target: NLRP3 in microglia (Iba1+ cells)
• Downstream: Block IL-1β/IL-18 release, reduce pyroptosis
• Outcome: Protect dopaminergic neurons in substantia nigra

Pipeline

Programs

| Program | Mechanism | Indication | Stage | Status |
|---------|-----------|------------|-------|--------|
| INN-101 | NLRP3 inhibitor | Parkinson's disease | Preclinical | IND-enabling |
| INN-102 | NLRP3 inhibitor | Alzheimer's disease | Discovery | Lead optimization |
| INN-103 | NLRP3/TREM2 dual | ALS | Discovery | Early stage |

INN-101 (Parkinson's Disease)

INN-101 is Inception's lead program:

• Mechanism: Direct NLRP3 inhibition (binds NACHT domain)
• Potency: IC50 = 15 nM in human monocyte assays
• BBB penetration: logBB = 0.6, brain/plasma = 0.55
• Dosing: Once-daily oral, 5 mg/kg effective in mice
• Safety: No observed toxicity in 28-day rat study

Preclinical efficacy in MPTP model:

• 55% reduction in tyrosine hydroxylase+ neuron loss
• 70% reduction in Iba1+ microglial activation
• Significant improvement in rotarod performance

INN-102 (Alzheimer's Disease)

INN-102 is optimized for Alzheimer's disease pathology:

• Rationale: Aβ and tau pathology both activate NLRP3
• Combination potential: With anti-amyloid antibodies

Research Collaborations

Inception has established key academic partnerships:

• UC San Diego: Dr. Paula Desplats - alpha-synuclein biology
• The Scripps Research Institute: Dr. Gabrielle T. - drug discovery
• University of Michigan: Dr. K. Kanneganti - NLRP3 biology

Funding

| Round | Amount | Year | Investors |
|-------|--------|------|-----------|
| Series A | $32M | 2021 | ARCH Venture, Omega Funds, MPM Capital |

Strategic Positioning

Inception positions itself as the "CNS-first" NLRP3 company:

| Company | Focus | Inception Differentiation |
|---------|-------|---------------------------|
| Inception | CNS-only, brain-penetrant | Dedicated CNS optimization |
| Olacteant | Peripheral + CNS | Broader, less CNS-specific |
| NodThera | CNS (NT-0796) | Earlier stage |
| Ventus | NLRP3 + Gasdermin | Different mechanism |

Development Milestones

gantt
title Inception Therapeutics PD Program
dateFormat YYYY
axisFormat %Y

section INN-101
Lead optimization :done, 2020, 2022
GLP toxicology :active, 2023, 2025
IND filing :2025, 2025
Phase 1 :2025, 2026
Phase 2 :2026, 2028

References

[Inception Therapeutics](https://www.inceptiontx.com)

[Martinon F et al., Inflammasome in neurodegeneration (2014)](https://pubmed.ncbi.nlm.nih.gov/25412641/)

See Also

• [NLRP3 Inflammasome Inhibitors for Parkinson's Disease](/mechanisms/nlrp3-inflammasome-inhibitors-parkinsons)
• [NodThera Ltd.](/companies/nodthera)
• [Ventus Therapeutics](/companies/ventus-therapeutics)
• [NLRP3 Inhibitors Investment Landscape](/investment/nlrp3-inflammasome)